These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 22889313)

  • 1. Toward rational fragment-based lead design without 3D structures.
    Henen MA; Coudevylle N; Geist L; Konrat R
    J Med Chem; 2012 Sep; 55(17):7909-19. PubMed ID: 22889313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Counting on Fragment Based Drug Design Approach for Drug Discovery.
    Kashyap A; Singh PK; Silakari O
    Curr Top Med Chem; 2018; 18(27):2284-2293. PubMed ID: 30499406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.
    Maurer T
    Methods Enzymol; 2011; 493():469-85. PubMed ID: 21371602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Process of Fragment-Based Lead Discovery-A Perspective from NMR.
    Ma R; Wang P; Wu J; Ruan K
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fragment-Based Ligand Designing.
    Katiyar SP; Malik V; Kumari A; Singh K; Sundar D
    Methods Mol Biol; 2018; 1762():123-144. PubMed ID: 29594771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and optimization of PDE10A inhibitors using fragment-based screening by nanocalorimetry and X-ray crystallography.
    Recht MI; Sridhar V; Badger J; Bounaud PY; Logan C; Chie-Leon B; Nienaber V; Torres FE
    J Biomol Screen; 2014 Apr; 19(4):497-507. PubMed ID: 24375910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NMR spectroscopy: the swiss army knife of drug discovery.
    Horst R; Farley KA; Kormos BL; Withka JM
    J Biomol NMR; 2020 Nov; 74(10-11):509-519. PubMed ID: 32617727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of potent inhibitors by fragment-linking strategies.
    Bedwell EV; McCarthy WJ; Coyne AG; Abell C
    Chem Biol Drug Des; 2022 Oct; 100(4):469-486. PubMed ID: 35854428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent progress in fragment-based lead discovery.
    Schulz MN; Hubbard RE
    Curr Opin Pharmacol; 2009 Oct; 9(5):615-21. PubMed ID: 19477685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives on Fragment-based Drug Discovery: A Strategy Applicable to Diverse Targets.
    Li Q; Kang C
    Curr Top Med Chem; 2021; 21(13):1099-1112. PubMed ID: 34348623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The rise of molecular simulations in fragment-based drug design (FBDD): an overview.
    Bissaro M; Sturlese M; Moro S
    Drug Discov Today; 2020 Sep; 25(9):1693-1701. PubMed ID: 32592867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining NMR and X-ray crystallography in fragment-based drug discovery: discovery of highly potent and selective BACE-1 inhibitors.
    Wyss DF; Wang YS; Eaton HL; Strickland C; Voigt JH; Zhu Z; Stamford AW
    Top Curr Chem; 2012; 317():83-114. PubMed ID: 21647837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Library Design Strategies To Accelerate Fragment-Based Drug Discovery.
    Troelsen NS; Clausen MH
    Chemistry; 2020 Sep; 26(50):11391-11403. PubMed ID: 32339336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NMR techniques for characterization of ligand binding: utility for lead generation and optimization in drug discovery.
    Moore JM
    Biopolymers; 1999; 51(3):221-43. PubMed ID: 10516573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fragment-based drug discovery using rational design.
    Jhoti H
    Ernst Schering Found Symp Proc; 2007; (3):169-85. PubMed ID: 18510103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fragment shuffling: an automated workflow for three-dimensional fragment-based ligand design.
    Nisius B; Rester U
    J Chem Inf Model; 2009 May; 49(5):1211-22. PubMed ID: 19413347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NMR-based platform for fragment-based lead discovery used in screening BRD4-targeted compounds.
    Yu JL; Chen TT; Zhou C; Lian FL; Tang XL; Wen Y; Shen JK; Xu YC; Xiong B; Zhang NX
    Acta Pharmacol Sin; 2016 Jul; 37(7):984-93. PubMed ID: 27238211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein X-ray Crystallography and Drug Discovery.
    Maveyraud L; Mourey L
    Molecules; 2020 Feb; 25(5):. PubMed ID: 32106588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in protein NMR provided by the NIGMS Protein Structure Initiative: impact on drug discovery.
    Montelione GT; Szyperski T
    Curr Opin Drug Discov Devel; 2010 May; 13(3):335-49. PubMed ID: 20443167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel prostaglandin D synthase inhibitors generated by fragment-based drug design.
    Hohwy M; Spadola L; Lundquist B; Hawtin P; Dahmén J; Groth-Clausen I; Nilsson E; Persdotter S; von Wachenfeldt K; Folmer RH; Edman K
    J Med Chem; 2008 Apr; 51(7):2178-86. PubMed ID: 18341273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.